```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS  3  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS  4  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS  5  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS  6  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS  7  APR 04  STN AnaVist, Version 1, to be discontinued
 NEWS  8  APR 15  WPIDS, WPINDEX, and WPIX enhanced with new
                  predefined hit display formats
 NEWS  9  APR 28  EMBASE Controlled Term thesaurus enhanced
 NEWS 10  APR 28  IMSRESEARCH reloaded with enhancements
 NEWS 11  MAY 30  INPAFAMDB now available on STN for patent family
                  searching
 NEWS 12  MAY 30  DGENE, PCTGEN, and USGENE enhanced with new homology
                  sequence search option
 NEWS 13  JUN 06  EPFULL enhanced with 260,000 English abstracts
 NEWS 14  JUN 06  KOREAPAT updated with 41,000 documents
 NEWS 15  JUN 13  USPATFULL and USPAT2 updated with 11-character
                  patent numbers for U.S. applications
 NEWS 16  JUN 19  CAS REGISTRY includes selected substances from
                  web-based collections
 NEWS 17  JUN 25  CA/CAplus and USPAT databases updated with IPC
                  reclassification data
 NEWS 18  JUN 30  AEROSPACE enhanced with more than 1 million U.S.
                  patent records
 NEWS 19  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 20  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 21  JUN 30  STN AnaVist enhanced with database content from EPFULL
 NEWS 22  JUL 28  CA/CAplus patent coverage enhanced
 NEWS 23  JUL 28  EPFULL enhanced with additional legal status
                  information from the epoline Register
 NEWS 24  JUL 28  IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
 NEWS 25  JUL 28  STN Viewer performance improved
 NEWS 26  AUG 01  INPADOCDB and INPAFAMDB coverage enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
```

```
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:35:04 ON 11 AUG 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'REGISTRY' ENTERED AT 07:35:21 ON 11 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 AUG 2008  HIGHEST RN 1040032-70-9
DICTIONARY FILE UPDATES:  10 AUG 2008  HIGHEST RN 1040032-70-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10573484.str
```



```
chain nodes :
7  17  18  19  20  21  29  31  32  33
ring nodes :
1  2  3  4  5  6  8  9  10  11  12  13  14  15  16  23  24  25  26  27  28
chain bonds :
2-18  3-20  4-21  5-19  6-7  7-12  11-17  29-31  29-32  29-33
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-12  9-10  9-13  10-11  10-16  11-12  13-14
14-15  15-16  23-24  23-28  24-25  25-26  26-27  27-28
exact/norm bonds :
4-21  6-7  7-12  8-9  8-12  10-11  11-12  29-31  29-32  29-33
exact bonds :
2-18  3-20  5-19  11-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-13  10-16  13-14  14-15  15-16  23-24  23-28
24-25  25-26  26-27  27-28
isolated ring systems :
containing 1 : 8 : 23 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom  29:CLASS
30:Atom  31:CLASS  32:CLASS  33:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 07:35:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       37 TO ITERATE

100.0% PROCESSED       37 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          376 TO     1104
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:35:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      645 TO ITERATE

100.0% PROCESSED      645 ITERATIONS                                41 ANSWERS
SEARCH TIME: 00.00.01

L3           41 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'CAPLUS' ENTERED AT 07:35:54 ON 11 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

FILE COVERS 1907 - 11 Aug 2008 VOL 149 ISS 7
FILE LAST UPDATED: 10 Aug 2008 (20080810/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3 full
L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:300447 CAPLUS
DOCUMENT NUMBER: 142:373838
TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030771	A1	20050407	WO 2004-EP52378	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276015	A1	20050407	AU 2004-276015	20040930
CA 2540083	A1	20050407	CA 2004-2540083	20040930
EP 1675854	A1	20060705	EP 2004-787263	20040930
EP 1675854	B1	20080625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856491	A	20061101	CN 2004-80027592	20040930
BR 2004014972	A	20061107	BR 2004-14972	20040930
JP 2007507467	T	20070329	JP 2006-530264	20040930
NO 2006001344	A	20060324	NO 2006-1344	20060324
MX 2006PA03349	A	20060608	MX 2006-PA3349	20060324
US 20070043073	A1	20070222	US 2006-573484	20060324
IN 2006MN00475	A	20070316	IN 2006-MN475	20060424

PRIORITY APPLN. INFO.: EP 2003-22053 A 20031001
WO 2004-EP52378 W 20040930
OTHER SOURCE(S): CASREACT 142:373838; MARPAT 142:373838
GI



H I



H II

AB Title compds. I [R1 = H, alkyl; R2 = H, alkyl; R3 = H, halo; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with N,N-dimethyl-4-bromobenzenesulfonamide. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 7.45 up to 7.86 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849357-47-7P 849357-48-8P 849357-49-9P
849357-50-2P 849357-51-3P 849357-52-4P
849357-54-6P 849357-55-7P 849357-56-8P
849357-57-9P 849357-58-0P 849357-59-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849357-47-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 849357-48-8 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-

imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849357-49-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



RN 849357-50-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849357-51-3 CAPLUS
CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849357-52-4 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 849357-54-6 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849357-55-7 CAPLUS
CN Benzenesulfonamide, 2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



RN 849357-56-8 CAPLUS
CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849357-57-9 CAPLUS
CN Benzenesulfonamide, N-ethyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



RN 849357-58-0 CAPLUS
CN Benzenesulfonamide, N,N-diethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849357-59-1 CAPLUS
CN Benzenesulfonamide, N-ethyl-2-fluoro-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:300446 CAPLUS
DOCUMENT NUMBER: 142:373837
TITLE: Preparation of imidazopyridine derivatives as inducible NO-synthase inhibitors
INVENTOR(S): Fuchss, Thomas; Martin, Thomas; Boer, Rainer; Strub, Andreas; Eltze, Manfrid; Lehner, Martin; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030770	A1	20050407	WO 2004-EP52377	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276014	A1	20050407	AU 2004-276014	20040930
CA 2540243	A1	20050407	CA 2004-2540243	20040930
EP 1670796	A1	20060621	EP 2004-787262	20040930
EP 1670796	B1	20080625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856495	A	20061101	CN 2004-80027833	20040930
BR 2004014933	A	20061107	BR 2004-14933	20040930
JP 2007507466	T	20070329	JP 2006-530263	20040930
NO 2006001317	A	20060323	NO 2006-1317	20060323
MX 2006PA03351	A	20060608	MX 2006-PA3351	20060324
US 20060293302	A1	20061228	US 2006-573202	20060324
US 7279488	B2	20071009		
IN 2006MN00362	A	20070615	IN 2006-MN362	20060331
US 20080021039	A1	20080124	US 2007-905033	20070927

PRIORITY APPLN. INFO.: EP 2003-22046 A 20031001
WO 2004-EP52377 W 20040930
US 2006-573202 A1 20060324
OTHER SOURCE(S): CASREACT 142:373837; MARPAT 142:373837
GI



H I



H II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkoxyalkyl, hydroxyalkyl, etc.; R3 = alkyl, CF3, completely or predominantly F-substituted alkoxy, etc.; R1 and R2 together = (un)saturated-, (un)substituted-nitrogen heterocycle; R4 = H, halo, alkyl, alkoxy; R5 = alkyl; A = alkylene] and their resp. pharmaceutically acceptable salts, are prepared and disclosed as inducible no-synthase inhibitors. Thus, e.g., II was prepared via Suzuki coupling of 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (preparation given) with 1-(4-bromo-benzenesulfonyl)-4-methyl-piperazine. The activity of I towards inducible NO-synthase was evaluated in inhibition assays and revealed -logIC50 values in the range of 6.51 up to 7.89 mol/L. I as inducible NO-synthase inhibitors should prove useful in the treatment of acute and chronic inflammatory diseases.

IT 849530-98-9P 849531-00-6P 849531-02-8P
849531-04-0P 849531-06-2P 849531-08-4P
849531-10-8P 849531-12-0P 849531-14-2P
849531-16-4P 849531-18-6P 849531-20-0P
849531-50-6P 849531-58-4P 849531-60-8P
849531-62-0P 849531-64-2P 849531-66-4P
849531-68-6P 849531-70-0P 849531-72-2P
849531-74-4P 849531-80-2P 849531-82-4P
849531-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridine derivs. as inducible NO-synthase inhibitors)

RN 849530-98-9 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-00-6 CAPLUS
CN Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-02-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 849531-04-0 CAPLUS
CN Benzenesulfonamide, N-cyclohexyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-06-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 849531-08-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl-2-(trifluoromethyl)- (CA INDEX NAME)



RN 849531-10-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N,N,3-trimethyl- (CA INDEX NAME)



RN 849531-12-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-phenyl- (CA INDEX NAME)



RN 849531-14-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-(4-methylphenyl)- (CA INDEX NAME)



RN 849531-16-4 CAPLUS
CN Benzenesulfonamide, N-(2-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-18-6 CAPLUS
CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-20-0 CAPLUS
CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



RN 849531-50-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-phenyl- (CA INDEX NAME)



RN 849531-58-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-(2-methylphenyl)- (CA INDEX NAME)



RN 849531-60-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-4-pyridinyl- (CA INDEX NAME)



RN 849531-62-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(4-methylphenyl)- (CA INDEX NAME)



RN 849531-64-2 CAPLUS
CN Benzenesulfonamide, N-[4-(dimethylamino)phenyl]-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



RN 849531-66-4 CAPLUS
CN Benzenesulfonamide, N-(2-fluoro-4-methylphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-68-6 CAPLUS
CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-70-0 CAPLUS
CN Benzenesulfonamide, N-(4-methoxyphenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl- (CA INDEX NAME)



RN 849531-72-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]-N-methyl-N-(2-methylphenyl)- (CA INDEX NAME)



RN 849531-74-4 CAPLUS
CN Benzenesulfonamide, N-(4-chlorophenyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-80-2 CAPLUS
CN Benzenesulfonamide, N,N-bis(2-methoxyethyl)-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-82-4 CAPLUS
CN Benzenesulfonamide, N-cyclobutyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



RN 849531-84-6 CAPLUS
CN Benzenesulfonamide, N-cyclopropyl-4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:777790 CAPLUS
DOCUMENT NUMBER: 139:292156
TITLE: Preparation of alkoxypyridines as inducible nitric oxide synthase (iNOS) inhibitors
INVENTOR(S): Boer, Rainer; Marx, Degenhard; Eltze, Manfrid; Klein, Thomas; Nave, Ruediger; Graedler, Ulrich; Fuchss, Thomas; Barsig, Johannes; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080607	A1	20031002	WO 2003-EP3076	20030325
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2480385	A1	20031002	CA 2003-2480385	20030325
AU 2003226706	A1	20031008	AU 2003-226706	20030325
EP 1490366	A1	20041229	EP 2003-744851	20030325
EP 1490366	B1	20080123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008785	A	20050111	BR 2003-8785	20030325
CN 1642955	A	20050720	CN 2003-806917	20030325
JP 2005525388	T	20050825	JP 2003-578361	20030325
NZ 535959	A	20060526	NZ 2003-535959	20030325
AT 384722	T	20080215	AT 2003-744851	20030325
ES 2300599	T3	20080616	ES 2003-744851	20030325
IN 2004MN00462	A	20050218	IN 2004-MN462	20040820
MX 2004PA09283	A	20050125	MX 2004-PA9283	20040923
US 20050171125	A1	20050804	US 2004-509396	20040924
US 7138399	B2	20061121		
ZA 2004007766	A	20060628	ZA 2004-7766	20040927
NO 2004004633	A	20041223	NO 2004-4633	20041027
HK 1078850	A1	20071109	HK 2005-110611	20051123
PRIORITY APPLN. INFO.:			EP 2002-7049 A	20020327
			WO 2003-EP3076 W	20030325

OTHER SOURCE(S): MARPAT 139:292156
GI



I



II

AB Title compds. I [wherein R1 = alkoxy; A = alkylene; B = (un)substituted 3H-imidazo[4,5-b]pyridin-2-yl, 9H-purin-8-yl; their salts, N-oxides, and salts of the N-oxides] were prepared as inducible NO-synthase (iNOS) inhibitor for treatment of acute inflammatory diseases and chronic inflammatory diseases of peripheral organs and central nervous system (CNS). For example, II (m.p. = 116-117°) was prepared by cyclocondensation of Me 3-(4-methoxypyridin-2-yl)propionate (preparation given) with 2,3-diaminopyridine in the presence of polyphosphoric acid at 160° for 1 h. Selected invention compds. inhibited iNOS with -logIC50 (M) in the range of 7.03-7.55. Thus, I and their pharmaceutical compns. are useful for treating acute inflammatory diseases, chronic inflammatory diseases of peripheral organs and CNS and cancer (no data).

IT 608880-84-8P, N-[4-[2-[2-(4-Methoxypyridin-2-yl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inducible NO-synthase inhibitor; preparation of alkoxypyridines as inducible NO-synthase inhibitors)

RN 608880-84-8 CAPLUS

CN Benzenesulfonamide, N-[4-[2-[2-(4-methoxy-2-pyridinyl)ethyl]-3H-imidazo[4,5-b]pyridin-6-yl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    17.79      196.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -2.40       -2.40

STN INTERNATIONAL LOGOFF AT 07:37:41 ON 11 AUG 2008
```